What is Bionano Genomics' operating income?

Bionano Genomics' total operating income in 2025 was -$33.34 million, based on the following breakdown: Total Gross Profit: $13.19 million Total Operating Expenses: $46.52 million

Bionano Genomics (BNGO) Financials

$1.08 -0.02 (-1.38%)

Closing price 03:58 PM Eastern

Extended Trading

$1.06 -0.01 (-0.93%)

As of 04:06 PM Eastern

Compare

Annual Income Statements for Bionano Genomics

This table shows Bionano Genomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-18	-30	-41	-72	-133	-232	-112	-26
Consolidated Net Income / (Loss)	-23	-18	-30	-41	-72	-133	-232	-112	-26
Net Income / (Loss) Continuing Operations	-23	-18	-30	-41	-72	-133	-232	-112	-26
Total Pre-Tax Income	-23	-18	-30	-41	-78	-131	-232	-112	-26
Total Operating Income	-23	-20	-26	-39	-77	-132	-215	-104	-33
Total Gross Profit	3.47	3.29	3.36	2.77	3.87	5.95	9.57	0.38	13
Total Revenue	9.51	12	10	8.50	18	28	36	31	29
Operating Revenue	9.51	12	10	8.50	18	28	36	31	29
Total Cost of Revenue	6.03	8.71	6.77	5.73	14	22	27	30	15
Operating Cost of Revenue	6.03	8.71	6.77	5.73	14	22	27	30	15
Total Operating Expenses	27	24	29	41	81	138	225	104	47
Selling, General & Admin Expense	14	14	20	31	58	89	93	52	35
Research & Development Expense	12	9.48	9.08	10	22	49	54	25	11
Impairment Charge	0.60	-	-	-	-	0.00	77	20	0.00
Restructuring Charge	-	-	-	-	-	-	0.74	8.02	0.00
Total Other Income / (Expense), net	-0.13	1.93	-3.92	-2.53	-1.05	0.99	-17	-8.00	7.01
Interest & Investment Income	-	-	-	0.00	0.24	1.51	3.31	2.10	1.11
Other Income / (Expense), net	0.46	3.66	-0.30	-0.01	1.72	-0.22	-20	-10	5.90
Income Tax Expense	0.02	0.02	0.02	0.03	-5.72	1.88	0.06	0.03	0.07
Basic Earnings per Share	($8.65)	($2.61)	($1.99)	($0.39)	($0.26)	($4.58)	($408.60)	($88.13)	($4.85)
Weighted Average Basic Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	28.92M	569K	1.27M	5.45M
Diluted Earnings per Share	($8.65)	($2.61)	($1.99)	($0.39)	($0.26)	($4.58)	($408.60)	($88.13)	($4.85)
Weighted Average Diluted Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	28.92M	569K	1.27M	5.45M
Weighted Average Basic & Diluted Shares Outstanding	2.70M	7.08M	14.98M	104.25M	276.78M	306.24M	54.69M	3.01M	11.09M

This table shows Bionano Genomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-113	-44	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30
Consolidated Net Income / (Loss)	-113	-44	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30
Net Income / (Loss) Continuing Operations	-113	-44	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30
Total Pre-Tax Income	-113	-44	-31	-16	-44	-20	-3.10	-6.85	-8.49	-7.90	-8.29
Total Operating Income	-113	-25	-31	-17	-44	-12	-8.47	-7.80	-8.54	-8.54	-7.90
Total Gross Profit	2.75	2.44	2.82	2.59	-8.45	3.42	2.94	3.48	3.37	3.40	3.25
Total Revenue	9.32	11	8.77	7.77	6.07	8.16	6.46	6.73	7.37	7.95	6.69
Operating Revenue	9.32	11	8.77	7.77	6.07	8.16	6.46	6.73	7.37	7.95	6.69
Total Cost of Revenue	6.57	8.28	5.95	5.19	15	4.75	3.52	3.26	4.00	4.55	3.44
Operating Cost of Revenue	6.57	8.28	5.95	5.19	15	4.75	3.52	3.26	4.00	4.55	3.44
Total Operating Expenses	116	27	34	20	35	15	11	11	12	12	11
Selling, General & Admin Expense	25	15	19	12	9.46	12	9.03	8.35	9.06	8.71	8.01
Research & Development Expense	14	12	9.78	6.83	4.72	3.48	2.37	2.93	2.84	3.23	3.14
Impairment Charge	77	-	0.45	0.00	20	-0.27	0.00	0.00	0.00	-	0.00
Restructuring Charge	0.00	0.74	4.63	1.22	1.77	0.41	0.00	0.00	0.00	-	0.00
Total Other Income / (Expense), net	0.69	-19	-0.32	0.82	-0.32	-8.18	5.37	0.95	0.05	0.64	-0.40
Interest & Investment Income	0.73	1.19	1.04	0.46	0.38	0.22	0.29	0.28	0.27	0.28	0.22
Other Income / (Expense), net	-0.05	-20	-1.36	0.36	-0.70	-8.41	5.08	0.68	-0.22	0.36	-0.62
Income Tax Expense	0.04	-0.04	-0.02	0.03	0.02	0.00	0.01	0.01	0.01	0.04	0.01
Basic Earnings per Share	($3.22)	($77.14)	($35.75)	($14.41)	($30.92)	($15.83)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)
Weighted Average Basic Shares Outstanding	35.00M	569K	879K	1.13M	1.43M	1.27M	2.69M	3.44M	5.34M	5.45M	10.98M
Diluted Earnings per Share	($3.22)	($77.14)	($35.75)	($14.41)	($30.92)	($15.83)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)
Weighted Average Diluted Shares Outstanding	35.00M	569K	879K	1.13M	1.43M	1.27M	2.69M	3.44M	5.34M	5.45M	10.98M
Weighted Average Basic & Diluted Shares Outstanding	38.84M	54.69M	66.86M	86.00M	101.99M	3.01M	3.36M	4.68M	10.18M	11.09M	11.48M

This table details how cash moves in and out of Bionano Genomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-4.23	16	0.79	21	-14	-19	13	-8.78	-5.06
Net Cash From Operating Activities	-21	-20	-30	-38	-72	-125	-125	-69	-16
Net Cash From Continuing Operating Activities	-21	-20	-30	-38	-72	-126	-124	-69	-16
Net Income / (Loss) Continuing Operations	-23	-18	-30	-41	-72	-133	-232	-112	-26
Consolidated Net Income / (Loss)	-23	-18	-30	-41	-72	-133	-232	-112	-26
Depreciation Expense	1.50	1.32	1.13	1.48	3.35	9.62	14	14	9.53
Amortization Expense	-	-	-	0.00	0.02	0.86	-0.34	-1.11	-0.77
Non-Cash Adjustments To Reconcile Net Income	0.96	-0.40	4.13	4.75	11	22	111	37	0.78
Changes in Operating Assets and Liabilities, net	0.09	-2.37	-4.97	-3.44	-13	-26	-16	-6.73	0.51
Net Cash From Investing Activities	-1.02	-0.33	-0.06	-2.45	-278	83	24	74	-13
Net Cash From Continuing Investing Activities	-1.02	-0.33	-0.06	-2.45	-278	82	24	74	-13
Purchase of Property, Plant & Equipment	-1.02	-0.33	-0.06	0.00	-0.82	-2.50	-1.69	-0.10	0.00
Purchase of Investments	-	-	-	0.00	-313	-84	-111	-233	-242
Sale and/or Maturity of Investments	-	-	-	0.00	86	201	137	307	229
Net Cash From Financing Activities	18	36	30	62	336	23	114	-14	24
Net Cash From Continuing Financing Activities	18	36	30	62	336	23	114	-14	24
Repayment of Debt	0.00	-7.45	-14	-7.26	-15	0.00	-14	-73	-4.88
Repurchase of Common Equity	-	-	0.00	-2.00	-1.70	-0.58	-1.44	-	-2.12
Issuance of Debt	0.00	24	24	2.54	0.00	0.00	80	18	0.00
Issuance of Common Equity	0.00	19	20	40	343	23	58	41	31
Other Financing Activities, net	0.01	0.00	1.00	29	10	0.31	-9.05	-0.06	-0.07
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.07	-0.01	-0.01
Cash Interest Paid	0.53	0.70	1.28	1.25	1.91	0.30	1.65	11	1.67

This table details how cash moves in and out of Bionano Genomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	20	-17	-2.19	5.67	-13	0.38	-5.95	-0.06	-0.50	1.44	0.40
Net Cash From Operating Activities	-26	-30	-28	-21	-13	-6.50	-2.76	-3.49	-5.92	-4.18	-5.72
Net Cash From Continuing Operating Activities	-26	-29	-28	-21	-13	-6.50	-2.76	-3.49	-5.92	-4.18	-5.72
Net Income / (Loss) Continuing Operations	-113	-44	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30
Consolidated Net Income / (Loss)	-113	-44	-31	-16	-44	-20	-3.10	-6.86	-8.50	-7.93	-8.30
Depreciation Expense	3.63	3.60	3.01	2.99	5.63	2.40	2.43	2.38	2.38	2.34	2.31
Amortization Expense	-0.03	-0.18	-0.64	-0.17	-0.21	-0.09	-0.19	-0.20	-0.19	-0.20	-0.14
Non-Cash Adjustments To Reconcile Net Income	81	22	-3.69	1.22	30	9.29	-3.93	1.95	1.40	1.36	1.05
Changes in Operating Assets and Liabilities, net	1.39	-10	4.66	-8.84	-4.58	2.03	2.02	-0.76	-1.01	0.26	-0.63
Net Cash From Investing Activities	33	-55	48	29	-5.38	3.00	-14	1.98	-4.67	4.01	5.46
Net Cash From Continuing Investing Activities	34	-55	48	29	-5.38	3.00	-14	1.98	-4.67	4.01	5.46
Purchase of Investments	-4.49	-107	-111	-41	-63	-19	-65	-52	-61	-64	-49
Sale and/or Maturity of Investments	38	52	158	70	57	22	51	54	56	68	54
Net Cash From Financing Activities	13	68	-22	-1.98	6.02	3.89	11	1.47	10	1.60	0.66
Net Cash From Continuing Financing Activities	13	68	-22	-1.98	6.02	3.89	11	1.47	10	1.60	0.66
Repayment of Debt	-	-14	-37	-31	-3.00	-2.30	-1.50	-1.50	-1.88	-	0.00
Repurchase of Common Equity	-0.32	-0.28	-0.39	-0.98	-1.08	-	-0.92	-0.10	-0.97	-0.13	-0.03
Issuance of Common Equity	13	11	15	12	10	3.77	13	3.09	13	1.75	0.71
Other Financing Activities, net	-0.01	-9.01	-0.01	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02	-0.02
Effect of Exchange Rate Changes	-0.01	0.05	-0.03	-0.00	0.02	-0.00	-0.01	-	0.02	0.01	0.01
Cash Interest Paid	0.07	1.43	5.62	4.05	0.47	0.52	0.48	0.44	0.39	0.36	0.36

This table presents Bionano Genomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	10	25	30	60	377	308	214	77	74
Total Current Assets	7.14	23	28	47	272	157	140	39	45
Cash & Equivalents	1.02	17	17	38	25	5.09	18	9.17	2.99
Restricted Cash	-	-	-	-	-	0.00	35	11	10
Short-Term Investments	-	-	-	0.00	226	108	49	0.30	16
Accounts Receivable	3.35	4.51	6.33	2.78	4.93	7.02	9.32	4.75	5.20
Inventories, net	1.69	1.07	3.44	3.32	12	30	23	11	5.45
Prepaid Expenses	1.07	0.92	1.17	2.25	4.48	7.33	6.02	3.14	5.20
Plant, Property, & Equipment, net	3.01	1.78	1.95	4.91	10	18	23	19	15
Total Noncurrent Assets	0.00	0.00	0.00	8.75	94	132	51	18	13
Noncurrent Note & Lease Receivables	-	-	-	-	3.93	3.71	3.50	3.30	3.10
Intangible Assets	-	-	0.00	1.48	27	41	34	9.71	4.35
Other Noncurrent Operating Assets	-	-	0.00	0.10	7.44	10	13	4.96	5.91
Total Liabilities & Shareholders' Equity	10	25	30	60	377	308	214	77	74
Total Liabilities	17	15	27	25	40	58	118	41	29
Total Current Liabilities	17	4.52	26	8.95	22	36	100	37	23
Accounts Payable	2.30	1.35	2.70	2.93	11	13	10	6.96	5.59
Accrued Expenses	3.51	2.90	3.23	5.60	8.62	11	8.09	5.64	5.46
Current Deferred Revenue	0.21	0.27	0.36	0.42	0.68	0.87	0.78	1.13	0.97
Other Current Liabilities	3.90	-	-	-	1.77	2.55	81	24	11
Total Noncurrent Liabilities	0.71	10	0.23	16	18	22	18	3.95	6.22
Noncurrent Deferred Revenue	0.14	0.30	0.18	0.10	0.15	0.13	0.15	0.27	0.25
Other Noncurrent Operating Liabilities	0.57	0.81	0.04	-	18	22	18	3.68	5.97
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-50	10	3.61	35	337	249	96	35	44
Total Preferred & Common Equity	-50	10	3.61	35	337	249	96	35	44
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-50	10	3.61	35	337	249	96	35	44
Common Stock	4.04	83	106	179	554	599	677	729	764
Retained Earnings	-54	-73	-103	-144	-216	-349	-581	-693	-720
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-0.54	-1.12	0.02	0.03	0.02

This table presents Bionano Genomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	182	158	129	87	78	76	79	65
Total Current Assets	105	86	61	47	45	43	49	39
Cash & Equivalents	35	16	10	8.79	3.63	3.56	3.07	3.43
Restricted Cash	-	24	11	11	11	11	10	10
Short-Term Investments	29	13	8.52	3.16	15	13	19	11
Accounts Receivable	8.67	8.31	6.26	5.32	3.35	3.49	4.53	4.13
Inventories, net	26	20	19	14	9.56	8.63	7.05	5.31
Prepaid Expenses	5.86	4.95	4.89	4.39	2.78	3.10	5.38	4.86
Plant, Property, & Equipment, net	21	25	25	20	18	17	16	14
Total Noncurrent Assets	56	47	44	20	15	16	14	12
Noncurrent Note & Lease Receivables	3.56	3.45	3.40	3.35	3.25	3.20	3.15	3.04
Intangible Assets	36	32	30	11	8.37	7.03	5.69	3.01
Other Noncurrent Operating Assets	17	12	11	5.99	3.53	5.86	5.26	5.74
Total Liabilities & Shareholders' Equity	182	158	129	87	78	76	79	65
Total Liabilities	63	75	49	38	30	31	29	27
Total Current Liabilities	40	59	37	33	26	24	23	21
Accounts Payable	15	9.84	8.73	8.70	6.56	6.24	5.99	5.06
Accrued Expenses	12	11	5.53	5.88	3.94	3.41	4.71	4.00
Current Deferred Revenue	0.81	1.04	1.15	1.20	1.02	1.17	1.18	1.13
Other Current Liabilities	2.46	37	22	17	15	13	11	11
Total Noncurrent Liabilities	23	17	12	5.54	3.82	6.46	6.29	6.11
Noncurrent Deferred Revenue	0.15	0.14	0.27	0.26	0.29	0.24	0.19	0.14
Other Noncurrent Operating Liabilities	23	17	12	5.28	3.53	6.22	6.09	5.97
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	119	83	80	49	48	45	50	37
Total Preferred & Common Equity	119	83	80	49	48	45	50	37
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	119	83	80	49	48	45	50	37
Common Stock	656	695	709	720	745	749	761	765
Retained Earnings	-537	-613	-629	-673	-696	-703	-712	-728
Accumulated Other Comprehensive Income / (Loss)	-0.09	-0.02	-0.00	1.53	0.01	-0.01	0.01	0.01

This table displays calculated financial ratios and metrics derived from Bionano Genomics' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	10,032,687.00	26,489,740.00	153,186,000.00	289,184,109.00	296,924,500.00	38,840,337.00	101,993,225.00	10,176,000.00
DEI Adjusted Shares Outstanding	0.00	16,721.00	44,150.00	255,310.00	481,974.00	494,874.00	647,339.00	1,699,887.00	10,176,000.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1,106.18	-675.31	-161.00	-150.29	-267.94	-359.15	-65.90	-2.59
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	26.26%	-15.59%	-16.06%	111.47%	54.62%	29.90%	-14.79%	-7.37%
EBITDA Growth	0.00%	27.36%	-62.25%	-48.04%	-94.22%	-68.64%	-83.11%	54.50%	81.53%
EBIT Growth	0.00%	26.36%	-56.19%	-47.31%	-95.51%	-75.00%	-78.70%	51.61%	75.95%
NOPAT Growth	0.00%	12.08%	-26.74%	-48.99%	-100.00%	-70.81%	-63.44%	51.69%	67.94%
Net Income Growth	0.00%	20.84%	-61.19%	-37.87%	-76.22%	-83.06%	-75.34%	51.82%	76.44%
EPS Growth	0.00%	69.83%	23.75%	80.40%	33.33%	-83.06%	-75.34%	51.82%	94.50%
Operating Cash Flow Growth	0.00%	4.20%	-48.06%	-29.75%	-87.73%	-73.53%	-0.29%	44.94%	76.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-18.50%	-53.54%	-280.01%	-18.63%	100.43%	-14,395.20%	75.03%
Invested Capital Growth	0.00%	275.19%	141.58%	102.87%	567.59%	68.31%	-103.94%	359.99%	-0.07%
Revenue Q/Q Growth	0.00%	0.00%	-10.79%	16.44%	14.76%	7.39%	7.46%	-7.67%	-0.74%
EBITDA Q/Q Growth	0.00%	0.00%	-3.32%	-11.33%	-29.26%	-7.00%	-3.23%	19.00%	39.12%
EBIT Q/Q Growth	0.00%	0.00%	-3.84%	-11.67%	-30.49%	-7.16%	-3.34%	17.88%	30.73%
NOPAT Q/Q Growth	0.00%	0.00%	-4.28%	-11.47%	-29.70%	-7.11%	5.52%	11.12%	9.27%
Net Income Q/Q Growth	0.00%	0.00%	-5.26%	-10.27%	-18.33%	-13.46%	-2.29%	17.50%	31.60%
EPS Q/Q Growth	0.00%	0.00%	-4.19%	-39.29%	-18.18%	-13.46%	-2.29%	17.50%	32.92%
Operating Cash Flow Q/Q Growth	0.00%	-6.86%	-21.83%	-7.65%	-23.14%	-7.67%	3.65%	25.24%	12.47%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-5.18%	-181.60%	16.62%	100.57%	-120.37%	-31.35%
Invested Capital Q/Q Growth	0.00%	0.00%	54.76%	9.60%	458.25%	31.34%	-108.76%	-42.50%	-17.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	36.55%	27.41%	33.18%	32.61%	21.55%	21.38%	26.49%	1.23%	46.25%
EBITDA Margin	-223.58%	-128.64%	-247.26%	-436.07%	-400.51%	-436.81%	-615.71%	-328.75%	-65.54%
Operating Margin	-244.28%	-170.12%	-255.44%	-453.38%	-428.79%	-473.70%	-595.98%	-337.87%	-116.95%
EBIT Margin	-239.41%	-139.64%	-258.40%	-453.46%	-419.25%	-474.50%	-652.74%	-370.69%	-96.25%
Profit (Net Income) Margin	-245.82%	-154.13%	-294.34%	-483.43%	-402.84%	-476.93%	-643.74%	-363.98%	-92.59%
Tax Burden Percent	100.08%	100.08%	100.07%	100.07%	92.68%	101.44%	100.03%	100.03%	100.25%
Interest Burden Percent	102.60%	110.28%	113.83%	106.53%	103.67%	99.08%	98.60%	98.16%	95.95%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,518.66%	-401.10%	-278.99%	-108.52%	-79.44%	-215.46%	-1,587.70%	-156.68%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,047.55%	94.79%	-133.05%	-94.98%	-56.64%	-135.90%	-1,523.58%	-144.46%
Return on Net Nonoperating Assets (RNNOA)	0.00%	1,251.90%	-32.54%	66.53%	69.60%	34.22%	80.89%	1,417.37%	90.53%
Return on Equity (ROE)	323.75%	-1,266.76%	-433.64%	-212.46%	-38.92%	-45.21%	-134.56%	-170.33%	-66.15%
Cash Return on Invested Capital (CROIC)	0.00%	-697.57%	-484.00%	-346.92%	-256.41%	-130.35%	0.00%	-626.97%	-156.61%
Operating Return on Assets (OROA)	-224.30%	-95.90%	-95.16%	-85.06%	-34.46%	-38.54%	-90.34%	-78.39%	-36.52%
Return on Assets (ROA)	-230.31%	-105.85%	-108.40%	-90.68%	-33.11%	-38.74%	-89.09%	-76.97%	-35.13%
Return on Common Equity (ROCE)	2,253.15%	17,390.16%	-433.64%	-212.46%	-38.92%	-45.21%	-134.56%	-170.33%	-66.15%
Return on Equity Simple (ROE_SIMPLE)	46.52%	-182.46%	-825.05%	-117.17%	-21.49%	-53.17%	-241.78%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-14	-18	-27	-54	-92	-151	-73	-23
NOPAT Margin	-171.00%	-119.08%	-178.81%	-317.37%	-300.15%	-331.59%	-417.19%	-236.51%	-81.86%
Net Nonoperating Expense Percent (NNEP)	124.60%	-471.11%	-495.90%	-145.94%	-13.54%	-22.80%	-79.56%	-64.12%	-12.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-156.69%	-205.76%	-52.53%
Cost of Revenue to Revenue	63.45%	72.59%	66.82%	67.39%	78.46%	78.62%	73.51%	98.77%	53.75%
SG&A Expenses to Revenue	148.13%	118.50%	198.98%	365.38%	325.29%	318.67%	256.83%	168.49%	123.30%
R&D to Revenue	126.35%	79.03%	89.65%	120.62%	125.05%	176.42%	149.61%	80.59%	39.90%
Operating Expenses to Revenue	280.83%	197.53%	288.62%	485.99%	450.34%	495.08%	622.47%	339.11%	163.20%
Earnings before Interest and Taxes (EBIT)	-23	-17	-26	-39	-75	-132	-236	-114	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-15	-25	-37	-72	-121	-222	-101	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.19	9.09	13.45	2.56	1.74	0.76	0.83	0.35
Price to Tangible Book Value (P/TBV)	0.00	5.19	9.09	17.85	3.40	3.31	1.18	1.15	0.39
Price to Revenue (P/Rev)	2.17	4.38	3.24	55.49	48.09	15.59	2.03	0.96	0.55
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	17.05	5.58	34.70	7.10	2.26	0.00	0.60	0.00
Enterprise Value to Revenue (EV/Rev)	7.29	3.76	3.52	52.89	34.15	11.86	0.00	0.29	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.93	0.89	5.56	0.47	0.00	0.04	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.89	0.00	0.47	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.79	-0.61	-0.34	-0.50	-0.73	-0.60	-0.60	-0.93	-0.63
Leverage Ratio	-1.41	11.97	4.00	2.34	1.18	1.17	1.51	2.21	1.88
Compound Leverage Factor	-1.44	13.20	4.55	2.50	1.22	1.16	1.49	2.17	1.81
Debt to Total Capital	-1,380.97%	47.11%	84.75%	31.76%	0.00%	3.63%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	-1,380.97%	0.00%	84.75%	0.00%	0.00%	3.63%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	47.11%	0.00%	31.76%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-8,825.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	10,306.78%	52.89%	15.25%	68.24%	100.00%	96.37%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.32	-0.58	-0.80	-0.44	0.00	-0.08	0.00	0.00	0.00
Net Debt to EBITDA	-0.27	0.49	-0.11	0.60	0.00	0.85	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.58	0.00	-0.44	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.41	-0.63	-1.11	-0.61	0.00	-0.10	0.00	0.00	0.00
Net Debt to NOPAT	-0.35	0.52	-0.15	0.82	0.00	1.13	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.63	0.00	-0.61	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-14.37	-2.81	-6.46	6.62	12.36	2.04	-6.66	-16.71	-13.85
Noncontrolling Interest Sharing Ratio	-595.95%	1,472.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.43	5.09	1.07	5.23	12.47	4.38	1.40	1.06	1.98
Quick Ratio	0.26	4.65	0.90	4.61	11.70	3.35	0.76	0.38	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-18	-22	-34	-128	-151	0.65	-93	-23
Operating Cash Flow to CapEx	-2,045.31%	-6,012.33%	-48,364.98%	0.00%	-8,750.24%	-5,049.19%	-7,402.78%	-66,914.56%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-10.70	-6.04	-13.32	-42.46	-507.64	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-35.23	-11.57	-8.16	-15.21	-23.95	-418.85	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-36.95	-11.77	-8.17	-15.21	-24.23	-427.14	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.94	0.69	0.37	0.19	0.08	0.08	0.14	0.21	0.38
Accounts Receivable Turnover	2.84	3.05	1.87	1.87	4.66	4.65	4.42	4.37	5.73
Inventory Turnover	3.56	6.31	3.00	1.70	1.80	1.04	1.01	1.79	1.85
Fixed Asset Turnover	3.16	5.02	5.44	2.48	2.36	1.96	1.75	1.45	1.67
Accounts Payable Turnover	2.62	4.77	3.34	2.04	2.06	1.88	2.32	3.50	2.44
Days Sales Outstanding (DSO)	128.73	119.63	195.45	195.51	78.24	78.48	82.57	83.44	63.71
Days Inventory Outstanding (DIO)	102.51	57.87	121.67	215.26	203.13	351.92	361.93	204.22	197.34
Days Payable Outstanding (DPO)	139.39	76.57	109.23	179.29	177.22	194.57	157.53	104.15	149.50
Cash Conversion Cycle (CCC)	91.85	100.93	207.89	231.48	104.16	235.83	286.97	183.51	111.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-1.51	2.64	6.39	13	87	146	-5.73	15	15
Invested Capital Turnover	-6.30	21.15	2.24	0.88	0.36	0.24	0.52	6.71	1.91
Increase / (Decrease) in Invested Capital	0.00	4.15	3.74	6.57	74	59	-151	21	-0.01
Enterprise Value (EV)	69	45	36	450	614	330	-28	8.94	-14
Market Capitalization	21	53	33	472	865	434	73	29	16
Book Value per Share	($18.60)	$1.01	$0.14	$0.23	$1.17	$0.84	$2.48	$0.35	$4.37
Tangible Book Value per Share	($18.60)	$1.01	$0.14	$0.17	$0.88	$0.44	$1.60	$0.25	$3.94
Total Capital	-0.49	19	24	51	337	259	96	35	44
Total Debt	6.73	9.03	20	16	0.00	9.38	0.00	0.00	0.00
Total Long-Term Debt	0.00	9.03	0.00	16	0.00	0.00	0.00	0.00	0.00
Net Debt	5.71	-7.49	2.77	-22	-251	-104	-102	-20	-30
Capital Expenditures (CapEx)	1.02	0.33	0.06	0.00	0.82	2.47	1.69	0.10	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.81	1.98	4.66	-0.61	-0.04	18	-62	-18	-7.09
Debt-free Net Working Capital (DFNWC)	-2.78	19	22	38	251	131	40	2.15	22
Net Working Capital (NWC)	-9.51	19	1.89	38	251	121	40	2.15	22
Net Nonoperating Expense (NNE)	7.11	4.21	12	14	18	40	82	39	3.06
Net Nonoperating Obligations (NNO)	5.71	-7.49	2.77	-22	-251	-104	-102	-20	-30
Total Depreciation and Amortization (D&A)	1.50	1.32	1.13	1.48	3.37	10	13	13	8.76
Debt-free, Cash-free Net Working Capital to Revenue	-40.03%	16.50%	46.05%	-7.12%	-0.21%	63.34%	-171.11%	-59.56%	-24.87%
Debt-free Net Working Capital to Revenue	-29.28%	154.18%	216.95%	445.07%	1,393.55%	470.46%	111.00%	6.97%	78.73%
Net Working Capital to Revenue	-100.08%	154.18%	18.67%	445.07%	1,393.55%	436.71%	111.00%	6.97%	78.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	($4.60)	($408.60)	($88.13)	($4.85)
Adjusted Weighted Average Basic Shares Outstanding	270.11K	1.01M	3.78M	27.87M	28.96M	28.92M	569.17K	1.27M	5.45M
Adjusted Diluted Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	($4.60)	($408.60)	($88.13)	($4.85)
Adjusted Weighted Average Diluted Shares Outstanding	270.11K	1.01M	3.78M	27.87M	28.96M	28.92M	569.17K	1.27M	5.45M
Adjusted Basic & Diluted Earnings per Share	($86.50)	($26.10)	($19.90)	($3.90)	($2.60)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	270.11K	707.71K	1.50M	10.43M	27.68M	30.62M	911.57K	3.01M	11.09M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-14	-18	-27	-54	-92	-96	-53	-23
Normalized NOPAT Margin	-166.54%	-119.08%	-178.81%	-317.37%	-300.15%	-331.59%	-265.97%	-173.49%	-81.86%
Pre Tax Income Margin	-245.63%	-154.00%	-294.13%	-483.09%	-434.64%	-470.15%	-643.57%	-363.87%	-92.35%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-38.51	-9.72	-7.23	-15.31	-25.10	-442.69	0.00	0.00	0.00
NOPAT to Interest Expense	-27.50	-8.29	-5.00	-10.71	-17.97	-309.36	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-40.23	-9.92	-7.25	-15.31	-25.38	-450.98	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-29.23	-8.49	-5.02	-10.71	-18.25	-317.65	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-4.87%	-2.35%	-0.44%	-0.62%	0.00%	-8.04%

This table displays calculated financial ratios and metrics derived from Bionano Genomics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	35,348,440.00	38,840,337.00	54,694,000.00	66,856,804.00	85,997,130.00	101,993,225.00	3,007,000.00	3,364,000.00	4,681,000.00	10,176,000.00	11,092,000.00
DEI Adjusted Shares Outstanding	58,914.00	647,339.00	911,567.00	1,114,280.00	1,433,286.00	1,699,887.00	3,007,000.00	3,364,000.00	4,681,000.00	10,176,000.00	11,092,000.00
DEI Earnings Per Adjusted Shares Outstanding	-1,910.68	-67.80	-34.47	-14.56	-30.87	-11.84	-1.03	-2.04	-1.82	-0.78	-0.75
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	29.04%	30.51%	18.26%	-10.29%	-34.83%	-23.86%	-26.37%	-13.36%	21.31%	-2.60%	3.56%
EBITDA Growth	-270.87%	-20.02%	12.86%	61.96%	64.27%	56.82%	96.21%	64.28%	83.24%	66.55%	-455.95%
EBIT Growth	-252.34%	-20.30%	13.89%	57.91%	60.62%	54.97%	89.58%	57.23%	80.36%	59.83%	-151.58%
NOPAT Growth	-252.15%	33.51%	17.76%	56.63%	61.22%	52.14%	72.80%	54.17%	80.55%	28.52%	6.71%
Net Income Growth	-253.88%	-13.48%	15.36%	58.31%	60.69%	54.15%	90.13%	57.74%	80.78%	60.58%	-167.67%
EPS Growth	-192.73%	-13.48%	15.36%	58.31%	60.69%	54.15%	96.78%	86.19%	94.86%	90.78%	33.91%
Operating Cash Flow Growth	10.79%	13.73%	13.21%	42.83%	49.38%	78.16%	90.17%	83.38%	55.53%	35.81%	-106.80%
Free Cash Flow Firm Growth	71.31%	256.82%	221.37%	224.59%	125.95%	-121.66%	-94.51%	-68.39%	-77.37%	79.43%	-87.56%
Invested Capital Growth	-40.99%	-103.94%	-79.33%	-65.88%	-60.39%	359.99%	-36.82%	-64.40%	-30.72%	-0.07%	-32.52%
Revenue Q/Q Growth	7.57%	15.06%	-18.21%	-11.38%	-21.85%	34.41%	-20.90%	4.27%	9.42%	7.93%	-15.90%
EBITDA Q/Q Growth	-201.57%	61.91%	27.90%	54.07%	-183.23%	53.96%	93.67%	-332.75%	-32.86%	8.10%	-5.22%
EBIT Q/Q Growth	-186.23%	60.10%	28.12%	48.73%	-167.78%	54.37%	83.36%	-110.46%	-22.92%	6.67%	-4.20%
NOPAT Q/Q Growth	-188.53%	77.96%	-24.73%	45.32%	-157.97%	72.80%	29.11%	7.86%	-9.46%	0.02%	7.49%
Net Income Q/Q Growth	-189.28%	61.01%	28.41%	48.37%	-172.72%	54.52%	84.59%	-121.05%	-24.00%	6.70%	-4.66%
EPS Q/Q Growth	-159.68%	61.01%	28.41%	48.37%	-172.72%	54.52%	92.74%	-73.04%	20.10%	8.18%	47.95%
Operating Cash Flow Q/Q Growth	28.35%	-13.26%	5.53%	25.43%	36.56%	51.13%	57.50%	-26.16%	-69.74%	29.46%	-36.91%
Free Cash Flow Firm Q/Q Growth	50.67%	495.91%	-30.26%	-8.52%	-89.73%	-430.47%	117.67%	426.93%	-92.64%	-400.40%	110.68%
Invested Capital Q/Q Growth	-55.71%	-108.76%	623.56%	67.93%	-48.57%	-42.50%	27.23%	-5.39%	0.09%	-17.06%	-14.08%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	29.50%	22.75%	32.20%	33.26%	-139.07%	41.86%	45.50%	51.64%	45.74%	42.76%	48.63%
EBITDA Margin	-1,176.90%	-389.65%	-343.48%	-178.02%	-645.18%	-220.98%	-17.69%	-73.40%	-89.13%	-75.89%	-94.95%
Operating Margin	-1,214.98%	-232.74%	-354.92%	-218.99%	-722.89%	-146.28%	-131.10%	-115.85%	-115.90%	-107.36%	-118.09%
EBIT Margin	-1,215.46%	-421.52%	-370.44%	-214.32%	-734.37%	-249.27%	-52.42%	-105.81%	-118.87%	-102.79%	-127.35%
Profit (Net Income) Margin	-1,208.05%	-409.39%	-358.33%	-208.78%	-728.57%	-246.54%	-48.04%	-101.84%	-115.42%	-99.77%	-124.17%
Tax Burden Percent	100.03%	99.92%	99.94%	100.16%	100.05%	100.01%	100.23%	100.15%	100.16%	100.46%	100.12%
Interest Burden Percent	99.36%	97.20%	96.79%	97.26%	99.16%	98.90%	91.43%	96.11%	96.94%	96.62%	97.38%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-324.33%	-84.14%	-106.30%	-56.62%	-369.38%	-687.40%	-106.70%	-65.10%	-106.23%	-143.84%	-149.65%
ROIC Less NNEP Spread (ROIC-NNEP)	-294.64%	-58.45%	-92.45%	-47.73%	-334.06%	-668.17%	-113.59%	-60.23%	-97.01%	-136.01%	-139.36%
Return on Net Nonoperating Assets (RNNOA)	165.04%	34.79%	40.92%	15.69%	152.31%	621.59%	71.12%	27.50%	53.88%	85.24%	87.70%
Return on Equity (ROE)	-159.29%	-49.35%	-65.38%	-40.93%	-217.07%	-65.81%	-35.58%	-37.61%	-52.35%	-58.60%	-61.95%
Cash Return on Invested Capital (CROIC)	-129.39%	0.00%	-35.21%	-33.43%	-92.83%	-626.97%	-187.41%	-52.76%	-80.97%	-156.61%	-105.67%
Operating Return on Assets (OROA)	-161.60%	-58.34%	-61.67%	-39.13%	-181.82%	-52.71%	-12.62%	-28.26%	-41.03%	-39.01%	-51.11%
Return on Assets (ROA)	-160.61%	-56.66%	-59.65%	-38.11%	-180.39%	-52.13%	-11.57%	-27.20%	-39.84%	-37.86%	-49.83%
Return on Common Equity (ROCE)	-159.29%	-49.35%	-65.38%	-40.93%	-217.07%	-65.81%	-35.58%	-37.61%	-52.35%	-58.60%	-61.95%
Return on Equity Simple (ROE_SIMPLE)	-190.99%	0.00%	-274.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-79	-17	-22	-12	-31	-8.36	-5.93	-5.46	-5.98	-5.98	-5.53
NOPAT Margin	-850.49%	-162.92%	-248.44%	-153.30%	-506.02%	-102.40%	-91.77%	-81.09%	-81.13%	-75.15%	-82.67%
Net Nonoperating Expense Percent (NNEP)	-29.69%	-25.69%	-13.85%	-8.89%	-35.32%	-19.23%	6.89%	-4.87%	-9.22%	-7.83%	-10.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-18.16%	-26.32%	-14.83%	-62.89%	-23.63%	-12.30%	-12.03%	-12.00%	-13.45%	-14.76%
Cost of Revenue to Revenue	70.50%	77.25%	67.80%	66.74%	239.07%	58.14%	54.50%	48.36%	54.26%	57.24%	51.37%
SG&A Expenses to Revenue	267.18%	139.45%	217.68%	148.72%	155.84%	143.89%	139.89%	123.96%	123.04%	109.51%	119.78%
R&D to Revenue	147.94%	109.13%	111.52%	87.90%	77.67%	42.58%	36.70%	43.53%	38.60%	40.61%	46.94%
Operating Expenses to Revenue	1,244.48%	255.49%	387.13%	252.26%	583.81%	188.14%	176.60%	167.49%	161.64%	150.12%	166.73%
Earnings before Interest and Taxes (EBIT)	-113	-45	-32	-17	-45	-20	-3.39	-7.12	-8.76	-8.17	-8.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-110	-42	-30	-14	-39	-18	-1.14	-4.94	-6.57	-6.03	-6.35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.90	0.76	0.73	0.56	0.80	0.83	0.17	0.24	0.16	0.35	0.35
Price to Tangible Book Value (P/TBV)	1.29	1.18	1.19	0.90	1.03	1.15	0.21	0.29	0.18	0.39	0.38
Price to Revenue (P/Rev)	3.19	2.03	1.62	1.24	1.17	0.96	0.29	0.40	0.28	0.55	0.45
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.82	0.00	0.26	0.31	0.62	0.60	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.59	0.00	0.21	0.42	0.48	0.29	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.56	-0.60	-0.44	-0.33	-0.46	-0.93	-0.63	-0.46	-0.56	-0.63	-0.63
Leverage Ratio	1.26	1.51	1.43	1.36	1.60	2.21	1.81	1.63	1.69	1.88	1.67
Compound Leverage Factor	1.25	1.47	1.39	1.32	1.59	2.19	1.65	1.57	1.64	1.82	1.63
Debt to Total Capital	7.75%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	7.75%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	92.25%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-4.56	-3.73	-5.18	-6.18	-11.29	-12.67	-11.76	-12.39	-12.05	-12.98	-15.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.60	1.40	1.46	1.63	1.43	1.06	1.70	1.76	2.12	1.98	1.84
Quick Ratio	1.80	0.76	0.63	0.68	0.52	0.38	0.82	0.82	1.14	1.07	0.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-34	134	93	85	8.77	-29	5.12	27	1.99	-5.96	0.64
Operating Cash Flow to CapEx	-24,572.90%	-3,997.18%	-108,196.15%	-27,244.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.14	0.17	0.18	0.25	0.21	0.24	0.27	0.35	0.38	0.40
Accounts Receivable Turnover	4.64	4.42	4.97	5.28	4.77	4.37	4.88	5.63	5.84	5.73	7.68
Inventory Turnover	0.96	1.01	1.03	1.00	1.67	1.79	1.92	1.85	1.45	1.85	2.05
Fixed Asset Turnover	1.81	1.75	1.69	1.62	1.62	1.45	1.31	1.30	1.59	1.67	1.78
Accounts Payable Turnover	1.99	2.32	2.12	2.52	2.82	3.50	3.41	3.48	2.11	2.44	2.62
Days Sales Outstanding (DSO)	78.72	82.57	73.51	69.19	76.57	83.44	74.80	64.87	62.54	63.71	47.55
Days Inventory Outstanding (DIO)	380.66	361.93	354.24	364.75	219.18	204.22	190.19	196.99	251.35	197.34	178.07
Days Payable Outstanding (DPO)	183.22	157.53	172.24	145.02	129.45	104.15	107.05	104.97	172.76	149.50	139.21
Cash Conversion Cycle (CCC)	276.16	286.97	255.51	288.92	166.29	183.51	157.95	156.89	141.12	111.55	86.41
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	65	-5.73	30	50	26	15	19	18	18	15	13
Invested Capital Turnover	0.38	0.52	0.43	0.37	0.73	6.71	1.16	0.80	1.31	1.91	1.81
Increase / (Decrease) in Invested Capital	-45	-151	-115	-97	-40	21	-11	-32	-7.96	-0.01	-6.17
Enterprise Value (EV)	54	-28	7.94	15	16	8.94	-21	-16	-24	-14	-12
Market Capitalization	107	73	61	45	39	29	8.39	11	8.00	16	13
Book Value per Share	$3.37	$2.48	$1.51	$1.20	$0.57	$0.35	$0.47	$13.49	$10.64	$4.37	$3.38
Tangible Book Value per Share	$2.35	$1.60	$0.93	$0.75	$0.44	$0.25	$0.39	$11.40	$9.42	$3.94	$3.11
Total Capital	129	96	83	80	49	35	48	45	50	44	37
Total Debt	10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-54	-102	-53	-30	-23	-20	-29	-27	-32	-30	-25
Capital Expenditures (CapEx)	0.11	0.75	0.03	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	-62	-26	-6.56	-8.92	-18	-11	-8.95	-6.02	-7.09	-6.92
Debt-free Net Working Capital (DFNWC)	74	40	27	23	14	2.15	19	18	26	22	18
Net Working Capital (NWC)	64	40	27	23	14	2.15	19	18	26	22	18
Net Nonoperating Expense (NNE)	33	26	9.64	4.31	14	12	-2.82	1.40	2.53	1.96	2.78
Net Nonoperating Obligations (NNO)	-54	-102	-53	-30	-23	-20	-29	-27	-32	-30	-25
Total Depreciation and Amortization (D&A)	3.59	3.42	2.36	2.82	5.42	2.31	2.24	2.18	2.19	2.14	2.17
Debt-free, Cash-free Net Working Capital to Revenue	32.02%	-171.11%	-68.48%	-17.92%	-26.77%	-59.56%	-37.63%	-32.65%	-20.97%	-24.87%	-24.09%
Debt-free Net Working Capital to Revenue	221.19%	111.00%	72.34%	63.95%	42.09%	6.97%	65.07%	67.40%	89.91%	78.73%	61.75%
Net Working Capital to Revenue	191.44%	111.00%	72.34%	63.95%	42.09%	6.97%	65.07%	67.40%	89.91%	78.73%	61.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.22)	($4,628.40)	($36.00)	($14.40)	($31.20)	($949.80)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	35.00M	9.48K	878.98K	1.13M	1.43M	21.18K	2.69M	3.44M	5.34M	5.45M	10.98M
Adjusted Diluted Earnings per Share	($3.22)	($4,628.40)	($36.00)	($14.40)	($31.20)	($949.80)	($1.15)	($1.99)	($1.59)	($1.46)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	35.00M	9.48K	878.98K	1.13M	1.43M	21.18K	2.69M	3.44M	5.34M	5.45M	10.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	($4,628.40)	$0.00	$0.00	$0.00	($949.80)	$0.00	$0.00	$0.00	($1.46)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	38.84M	911.57K	1.11M	1.43M	1.70M	50.12K	3.36M	4.68M	10.18M	11.09M	11.48M
Normalized Net Operating Profit after Tax (NOPAT)	-25	-17	-18	-11	-16	-8.26	-5.93	-5.46	-5.98	-5.98	-5.53
Normalized NOPAT Margin	-269.93%	-158.08%	-207.89%	-142.35%	-260.81%	-101.23%	-91.77%	-81.09%	-81.13%	-75.15%	-82.67%
Pre Tax Income Margin	-1,207.63%	-409.73%	-358.54%	-208.44%	-728.17%	-246.53%	-47.93%	-101.69%	-115.23%	-99.32%	-124.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.51%	-0.62%	-0.64%	-0.96%	-2.00%	0.00%	0.00%	-3.52%	-6.50%	-8.04%	-3.90%

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics’ latest quarter shows a small improvement in cash generation, but the business is still operating at a meaningful loss. For Q1 2026, revenue rose to $6.7 million, while net loss was $8.3 million. The company also generated a modest $403,000 increase in cash and equivalents during the quarter, helped by strong activity in its investment portfolio and a small amount of equity issuance.

Looking at the last several quarters, the trend is mixed. Revenue has generally been fairly stable in the $6.5 million to $8.0 million range over the past year, but expenses remain well above gross profit, so losses continue. The biggest improvement came on the balance sheet side: cash and short-term investments remain sizable, which gives Bionano some near-term flexibility even though operating cash flow is still negative.

Revenue improved sequentially in Q1 2026 to $6.69 million from $7.95 million in Q4 2025 and $6.73 million in Q2 2025, showing the business is still producing meaningful top-line sales.
Gross profit remained positive at $3.25 million in Q1 2026, which means the core product and service sales still cover direct costs.
Cash and equivalents were $3.4 million at quarter-end, with additional restricted cash and short-term investments bringing current liquid resources much higher.
Total current assets of $39.0 million suggest the company still has liquidity runway beyond just cash on hand.
Investing activities added $5.5 million of cash in Q1 2026, driven by sales and maturities of investments exceeding purchases.
Q1 2026 financing added $657,000, mainly from common stock issuance, which helped offset operating losses.
Operating loss narrowed slightly quarter over quarter to $7.9 million in Q1 2026 from $8.5 million in Q3 2025 and $8.5 million in Q4 2025, but remains large.
Operating cash flow was still negative at $5.7 million in Q1 2026, indicating the company is not yet self-funding its operations.
SG&A and R&D remain elevated relative to gross profit, with total operating expenses of $11.1 million in Q1 2026 versus gross profit of $3.25 million.
Longer-term profitability remains weak; the company has posted losses in every quarter shown, including much larger losses in 2024 and 2025.

One encouraging sign is that Bionano has avoided the extreme impairment and restructuring charges seen in parts of 2024. In 2024, those items heavily distorted results, especially in Q3 2024 and Q4 2024. More recently, those charges have been absent or minimal, which makes the current results easier to compare and somewhat cleaner operationally.

Still, dilution is a risk to watch. The company has repeatedly used common stock issuance to support liquidity, and share counts remain an important issue for retail investors. While the balance sheet is not immediately distressed, ongoing losses and negative operating cash flow mean Bionano may continue to rely on external financing if profitability does not improve.

Bottom line: Bionano Genomics appears to have stabilized somewhat compared with the much weaker periods in 2024, but it is still a cash-burning company with limited evidence of sustainable earnings power. Investors will likely want to see either stronger revenue growth, better cost control, or a clear path to positive operating cash flow before the story improves materially.

07/30/26 04:07 PM ETAI Generated. May Contain Errors.

Bionano Genomics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bionano Genomics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bionano Genomics' net income appears to be on an upward trend, with a most recent value of -$26.40 million in 2025, rising from -$23.37 million in 2017. The previous period was -$112.02 million in 2024. See Bionano Genomics' forecast for analyst expectations on what's next for the company.

Bionano Genomics' total operating income in 2025 was -$33.34 million, based on the following breakdown:

Total Gross Profit: $13.19 million
Total Operating Expenses: $46.52 million

Over the last 8 years, Bionano Genomics' total revenue changed from $9.51 million in 2017 to $28.51 million in 2025, a change of 199.9%.

Bionano Genomics' total liabilities were at $29.16 million at the end of 2025, a 29.4% decrease from 2024, and a 68.0% increase since 2017.

In the past 8 years, Bionano Genomics' cash and equivalents has ranged from $1.02 million in 2017 to $38.45 million in 2020, and is currently $2.99 million as of their latest financial filing in 2025.

Over the last 8 years, Bionano Genomics' book value per share changed from -18.60 in 2017 to 4.37 in 2025, a change of -123.5%.

Related Companies

Financial statements for NASDAQ:BNGO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Financials

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Financials

Annual Income Statements for Bionano Genomics

Quarterly Income Statements for Bionano Genomics

Annual Cash Flow Statements for Bionano Genomics

Quarterly Cash Flow Statements for Bionano Genomics

Annual Balance Sheets for Bionano Genomics

Quarterly Balance Sheets for Bionano Genomics

Annual Metrics And Ratios for Bionano Genomics

Quarterly Metrics And Ratios for Bionano Genomics

Financials Breakdown Chart

Key Financial Trends

Bionano Genomics Financials - Frequently Asked Questions

When does Bionano Genomics' fiscal year end?

How has Bionano Genomics' net income changed over the last 8 years?

What is Bionano Genomics' operating income?

How has Bionano Genomics' revenue changed over the last 8 years?

How much debt does Bionano Genomics have?

How much cash does Bionano Genomics have?

How has Bionano Genomics' book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools